Clinical Trial

Hepatocellular Carcinoma Identification Using Delta-HLD

Study acronym: HIDE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated August 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-22.
Trial Details
NCT Number NCT07148310
Lead Sponsor Epiliquid Holding, Inc
Conditions Hepato Cellular Carcinoma (HCC)
Enrollment 200 participants
Start Date 2023-05-18
Primary Completion 2026-08-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-09